Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Rev. bras. anestesiol ; 66(1): 55-62, Jan.-Feb. 2016. tab
Article in Portuguese | LILACS | ID: lil-773487

ABSTRACT

BACKGROUND AND OBJECTIVES: residual paralysis following the use of neuromuscular blocking drugs (NMBDs) without neuromuscular monitoring remains a clinical problem, even when NMBDs are used. This study surveys postoperative residual curarization and critical respiratory events in the recovery room, as well as the clinical approach to PORC of anesthesiologists in our institution. METHODS: This observational study included 415 patients who received general anesthesia with intermediate-acting NMBDs. Anesthesia was maintained by non-participating anesthesiologists who were blinded to the study. Neuromuscular monitoring was performed upon arrival in the recovery room. A CRE was defined as requiring airway support, peripheral oxygen saturation <90% and 90-93% despite receiving 3 L/min nasal O2, respiratory rate >20 breaths/min, accessory muscle usage, difficulty with swallowing or speaking, and requiring reintubation. The clinical approach of our anesthesiologists toward reversal agents was examined using an 8-question mini-survey shortly after the study. RESULTS: The incidence of PORC was 43% (n = 179) for TOFR <0.9, and 15% (n = 61) for TOFR <0.7. The incidence of TOFR <0.9 was significantly higher in women, in those with ASA physical status 3, and with anesthesia of short duration (p < 0.05). In addition, 66% (n = 272) of the 415 patients arriving at the recovery room had received neostigmine. A TOFR <0.9 was found in 46% (n = 126) of the patients receiving neostigmine. CONCLUSIONS: When routine objective neuromuscular monitoring is not available, PORC remains a clinical problem despite the use of NMBDs. The timing and optimal antagonism of the neuromuscular blockade, and routine objective neuromuscular monitoring is recommended to enhance patient safety.


JUSTIFICATIVA E OBJETIVOS: A paralisia residual após o uso de bloqueadores neuromusculares (BNMs) sem monitoração neuromuscular continua sendo um problema clínico, mesmo quando BNMs são usados. Este estudo pesquisou a curarização residual pós-operatória e os eventos respiratórios críticos em sala de recuperação, bem como a abordagem clínica da CRPO feita pelos anestesiologistas em nossa instituição. MÉTODOS: Este estudo observacional incluiu 415 pacientes que receberam anestesia geral com BNMs de ação intermediária. A manutenção da anestesia foi feita por anestesiologistas não participantes, "cegos" para o estudo. A monitoração neuromuscular foi realizada no momento da chegada à sala de recuperação. Um ERC foi definido como necessidade de suporte ventilatório; saturação periférica de oxigênio <90% e 90-93%, a despeito de receber 3 L/min de O2 via cânula nasal; frequência respiratória >20 bpm; uso de musculatura acessória; dificuldade de engolir ou falar e necessidade de reintubação. A abordagem clínica de nossos anestesiologistas, em relação aos agentes de reversão, foi avaliada usando um miniquestionário de oito perguntas logo após o estudo. RESULTADOS: A incidência de CRPO foi de 43% (n = 179) para a SQE <0 e 15% (n = 61) para a SQE <0,7. A incidência de SQE <0,9 foi significativamente maior em mulheres, pacientes com estado físico ASA III e com anestesia de curta duração (p < 0,05). Além disso, 66% (n = 272) dos 415 pacientes que chegam à sala de recuperação haviam recebido neostigmina. Uma SQE <0,9 foi encontrada em 46% (n = 126) dos pacientes que receberam neostigmina. CONCLUSÃO: Quando a monitoração neuromuscular objetiva de rotina não está disponível, a CRPO continua sendo um problema clínico, a despeito do uso de BNMs. O momento e o antagonismo ideais do bloqueio neuromuscular e a monitoração neuromuscular objetiva de rotina são recomendados para aumentar a segurança do paciente.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Aged , Young Adult , Neuromuscular Blockade/methods , Delayed Emergence from Anesthesia/epidemiology , Neuromuscular Monitoring/methods , Neostigmine/administration & dosage , Neuromuscular Blocking Agents/administration & dosage , Time Factors , Sex Factors , Prospective Studies , Surveys and Questionnaires , Anesthesiologists/statistics & numerical data , Anesthesia, General/methods , Middle Aged
2.
Int. braz. j. urol ; 41(4): 669-675, July-Aug. 2015. tab
Article in English | LILACS | ID: lil-763070

ABSTRACT

ABSTRACTPurpose:We compared the effects of local levobupivacaine infiltration, intravenous paracetamol, intravenous lornoxicam treatments on postoperative analgesia in patients submitted to transperitoneal laparoscopic renal and adrenal surgery.Materials and Methods:Sixty adult patients 26 and 70 years who underwent laparoscopic renal and adrenal surgery were randomized into three groups with 20 patients each: Group 1 received local 20mL of levobupivacaine 0.25% infiltration to the trocar incisions before skin closure. In group 2, 1g paracetamol was given to the patients intravenously 30 minutes before extubation and 5g paracetamol was given intravenoulsy in the 24 postoperative period. In group 3, 8mg lornoxicam i.v. was given 30 minutes before extubation and 8mg lornoxicam i.v. was given in the 24 postoperative period. In the postoperative period, pain scores, cumulative tramadol, and additional pethidine consumption were evaluated.Results:Postoperative pain scores significantly reduced in each group (p < 0.05). Although pain levels of the groups were not significantly different at 1, 2, 4, 8, 12 and 24 hours postoperatively, cumulative tramadol consumptions were higher in group 1 than the others. (Group 1 = 370.6 ± 121.6mg, Group 2: 220.9 ± 92.5mg, Group 3 = 240.7 ± 100.4mg.) (p < 0.005). The average dose of pethidine administered was significantly lower in groups 2 and 3 compared with group 1 (Group 1: 145mg, Group 2: 100mg, Group 3: 100mg) (p = 0.024).Conclusions:Levobupivacaine treated group required significantly more intravenous tramadol when compared with paracetamol and lornoxicam groups in patients submitted to transperitoneal laparoscopic renal and adrenal surgery.


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Adrenal Glands/surgery , Kidney/surgery , Laparoscopy/methods , Pain Management/methods , Pain, Postoperative/drug therapy , Administration, Intravenous , Acetaminophen/administration & dosage , Acetaminophen/therapeutic use , Analgesics, Non-Narcotic/therapeutic use , Anesthesia, Local/methods , Anesthetics, Local/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Bupivacaine/analogs & derivatives , Bupivacaine/therapeutic use , Pain Measurement/methods , Piroxicam/administration & dosage , Piroxicam/analogs & derivatives , Piroxicam/therapeutic use , Visual Analog Scale
3.
Rev. bras. anestesiol ; 63(1): 144-148, jan.-fev. 2013. ilus, tab
Article in Portuguese | LILACS | ID: lil-666126

ABSTRACT

JUSTIFICATIVA E OBJETIVOS: Avaliar os potenciais efeitos neurotóxicos em nível ultraestrutural desulfato de magnésio administrado por via intratecal em dose única ou múltipla. MÉTODOS: Estudo realizado com 24 ratos Sprague-Dawley, peso médio entre 250 e 300 g. Apósjejum de 4 horas, os ratos receberam 10 mg.kg-1 de cloreto de xilazina por via intraperitoneale, em seguida, foram divididos aleatoriamente em três grupos. Grupo I (n = 8) recebeu 0,9% desoro fisiológico normal, Grupo II (n = 8) recebeu uma injeção de 0,02 mL de sulfato de magnésioa 15% por via intratecal e Grupo III (n = 8) recebeu 0,02 mL de sulfato de magnésio a 15% umavez por dia durante sete dias. As injeções foram aplicadas dentro de 0,40x50 milímetros daárea lombar. Após sete dias, os animais foram sacrificados sob anestesia com uma injeção deformaldeído a 10% na aorta e os tecidos foram fixados. A medula espinal foi, então, examinadae histopatologicamente avaliada sob microscópio eletrônico. O teste de Kruskal-Wallis foi usadopara avaliação estatística. Um valor de p < 0,05 foi considerado estatisticamente significativo. RESULTADOS: Neurodegeneração significativa foi detectada nos ratos que receberam uma únicainjeção ou injeções repetidas de sulfato de magnésio, em comparação com o grupo controle. O escore na avaliação histopatológica desse grupo também foi alto. CONCLUSÃO: Com base no exame de microscopia eletrônica, descobrimos que a administraçãointratecal de sulfato de magnésio induziu neurodegeneração.


BACKGROUND AND OBJECTIVES: To assess the potential neurotoxic effects at the ultrastructural level of magnesium sulfate administered intrathecally as a single or multi-dose. METHODS: Our study was conducted with 24 Sprague-Dawley rats that weighed 250-300 g. After a 4-hour fast, the rats were given 10 mg.kg-1 xylazine chloride intraperitoneal and then randomly allocated into three groups. Group I (n = 8) received 0.9% normal saline, Group II (n = 8) was given one intrathecal injection of 0.02 mL of 15% magnesium sulphate, and Group III (n = 8) was given 0.02 mL of 15% magnesium sulphate once a day for seven days. The injections were given within 0.40x50 mm from the lumbar area. After seven days, the animals were sacrificed under anesthesia with an aortic injection of 10% formaldehyde and their tissues were fixed. The medulla spinalis was then examined and histopathologically evaluated under an electron microscope. The Kruskal-Wallis test was used for statistical evaluation. A value of p < .05 was considered to be statistically significant. RESULTS: Significant neurodegeneration was detected in rats given single or repeated magnesium sulphate injections compared to the control group. The histopathological evaluation score of this group was also high. CONCLUSIONS: Based on electron microscopic examination, we found that intrathecal magnesium sulphate administration induced neurodegeneration.


JUSTIFICATIVA Y OBJETIVOS: Evaluar los potenciales efectos neurotóxicos en nivel ultraestructural de sulfuro de magnesio administrado por vía intratecal en dosis única o múltiple. MÉTODOS: Estudio realizado con 24 ratones Spraque-Dawley, con un peso promedio entre los 250 y los 300 g. Después del ayuno de 4 horas, los ratones recibieron 10 mg.kg-1 de cloruro de xilazina por vía intraperitoneal y enseguida fueron divididos aleatoriamente en tres grupos. El grupo I (n = 8) recibió 0,9% de suero fisiológico normal, Grupo II (n = 8) recibió una inyección de 0,02 mL de sulfuro de magnesio al 15% por vía intratecal y Grupo III (n = 8) recibió 0,02 mL de sulfuro de magnesio al 15% una vez por día durante siete días. Las inyecciones fueron aplicadas dentro de 0,40x50 milímetros del área lumbar. Después de siete días, los animales fueron sacrificados con anestesia con una inyección de formaldehido al 10% en la aorta y los tejidos fueron pegados. La médula espinal se examinó y fue histopatológicamente evaluada bajo microscopio electrónico. El test de Kruskal-Wallis fue usado para la evaluación estadística. Un valor de p < 0,05 fue considerado estadísticamente significativo. RESULTADOS: La neurodegeneración significativa fue detectada en los ratones que recibieron una sola inyección o inyecciones repetidas de sulfuro de magnesio, en comparación con el grupo control. El puntaje en la evaluación histopatológica de ese grupo también fue alto. CONCLUSIONES: Basándonos en el examen de microscopía electrónica, descubrimos que la administración intratecal de sulfuro de magnesio indujo a la neurodegeneración.


Subject(s)
Animals , Rats , Anesthetics/adverse effects , Magnesium Sulfate/adverse effects , Neurotoxicity Syndromes/etiology , Spinal Cord/pathology , Spinal Cord/ultrastructure , Anesthetics/administration & dosage , Injections, Spinal , Magnesium Sulfate/administration & dosage , Rats, Sprague-Dawley
SELECTION OF CITATIONS
SEARCH DETAIL